Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine in ARDS and COVID-19
NCT04609865Phase 3Terminated
- Sponsor
- Strasbourg University Hospital
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Lidocaine Hydrochloride Injection, without epinephrine in acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), sponsored by Strasbourg University Hospital. Started Nov 2020; status: terminated.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04609865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609865.